Galectins as therapeutic targets for hematological malignancies: A hopeful sweetness

Camilo Pena; Leonardo Mirandola; Jose A. Figueroa; Nattamol Hosiriluck; Natallia Suvorava; Kayley Trotter; Adair Reidy; Rahman Rakhshanda; Drew Payne; Marjorie Jenkins; Fabio Grizzi; Lauren Littlefield; Maurizio Chiriva-Internati; Everardo Cobos

doi:10.3978/j.issn.2305-5839.2014.09.14

Galectins as therapeutic targets for hematological malignancies: A hopeful sweetness

Camilo Pena, Leonardo Mirandola, Jose A. Figueroa, Nattamol Hosiriluck, Natallia Suvorava, Kayley Trotter, Adair Reidy, Rahman Rakhshanda, Drew Payne, Marjorie Jenkins, Fabio Grizzi, Lauren Littlefield, Maurizio Chiriva-Internati, Everardo Cobos

Medicine - Hematology, Oncology, Transplant

Research output: Contribution to journal › Article › peer-review

20 Scopus citations

Abstract

Galectins are family of galactose-binding proteins known to play critical roles in inflammation and neoplastic progression. Galectins facilitate the growth and survival of neoplastic cells by regulating their cross-talk with the extracellular microenvironment and hampering anti-neoplastic immunity. Here, we review the role of galectins in the biology of hematological malignancies and their promise as potential therapeutic agents in these diseases.

Original language	English (US)
Article number	87
Journal	Annals of Translational Medicine
Volume	2
Issue number	9
DOIs	https://doi.org/10.3978/j.issn.2305-5839.2014.09.14
State	Published - Sep 2014

Bibliographical note

Publisher Copyright:
© Annals of Translational Medicine. All rights reserved.

Keywords

Galectin-3 (Gal-3)
Galectins
Leukemia
Lymphomas
Multiple myeloma (MM)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.3978/j.issn.2305-5839.2014.09.14

OpenUrl availability

Full text

Cite this

Pena, C., Mirandola, L., Figueroa, J. A., Hosiriluck, N., Suvorava, N., Trotter, K., Reidy, A., Rakhshanda, R., Payne, D., Jenkins, M., Grizzi, F., Littlefield, L., Chiriva-Internati, M., & Cobos, E. (2014). Galectins as therapeutic targets for hematological malignancies: A hopeful sweetness. Annals of Translational Medicine, 2(9), Article 87. https://doi.org/10.3978/j.issn.2305-5839.2014.09.14

Pena, C, Mirandola, L, Figueroa, JA, Hosiriluck, N, Suvorava, N, Trotter, K, Reidy, A, Rakhshanda, R, Payne, D, Jenkins, M, Grizzi, F, Littlefield, L, Chiriva-Internati, M & Cobos, E 2014, 'Galectins as therapeutic targets for hematological malignancies: A hopeful sweetness', Annals of Translational Medicine, vol. 2, no. 9, 87. https://doi.org/10.3978/j.issn.2305-5839.2014.09.14

@article{a7521a9e9c174ff09856185ddf2ed207,

title = "Galectins as therapeutic targets for hematological malignancies: A hopeful sweetness",

abstract = "Galectins are family of galactose-binding proteins known to play critical roles in inflammation and neoplastic progression. Galectins facilitate the growth and survival of neoplastic cells by regulating their cross-talk with the extracellular microenvironment and hampering anti-neoplastic immunity. Here, we review the role of galectins in the biology of hematological malignancies and their promise as potential therapeutic agents in these diseases.",

keywords = "Galectin-3 (Gal-3), Galectins, Leukemia, Lymphomas, Multiple myeloma (MM)",

author = "Camilo Pena and Leonardo Mirandola and Figueroa, {Jose A.} and Nattamol Hosiriluck and Natallia Suvorava and Kayley Trotter and Adair Reidy and Rahman Rakhshanda and Drew Payne and Marjorie Jenkins and Fabio Grizzi and Lauren Littlefield and Maurizio Chiriva-Internati and Everardo Cobos",

year = "2014",

month = sep,

doi = "10.3978/j.issn.2305-5839.2014.09.14",

language = "English (US)",

volume = "2",

journal = "Annals of Translational Medicine",

issn = "2305-5839",

publisher = "AME Publishing Company",

number = "9",

}

TY - JOUR

T1 - Galectins as therapeutic targets for hematological malignancies

T2 - A hopeful sweetness

AU - Pena, Camilo

AU - Mirandola, Leonardo

AU - Figueroa, Jose A.

AU - Hosiriluck, Nattamol

AU - Suvorava, Natallia

AU - Trotter, Kayley

AU - Reidy, Adair

AU - Rakhshanda, Rahman

AU - Payne, Drew

AU - Jenkins, Marjorie

AU - Grizzi, Fabio

AU - Littlefield, Lauren

AU - Chiriva-Internati, Maurizio

AU - Cobos, Everardo

PY - 2014/9

Y1 - 2014/9

N2 - Galectins are family of galactose-binding proteins known to play critical roles in inflammation and neoplastic progression. Galectins facilitate the growth and survival of neoplastic cells by regulating their cross-talk with the extracellular microenvironment and hampering anti-neoplastic immunity. Here, we review the role of galectins in the biology of hematological malignancies and their promise as potential therapeutic agents in these diseases.

AB - Galectins are family of galactose-binding proteins known to play critical roles in inflammation and neoplastic progression. Galectins facilitate the growth and survival of neoplastic cells by regulating their cross-talk with the extracellular microenvironment and hampering anti-neoplastic immunity. Here, we review the role of galectins in the biology of hematological malignancies and their promise as potential therapeutic agents in these diseases.

KW - Galectin-3 (Gal-3)

KW - Galectins

KW - Leukemia

KW - Lymphomas

KW - Multiple myeloma (MM)

UR - http://www.scopus.com/inward/record.url?scp=85015484827&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015484827&partnerID=8YFLogxK

U2 - 10.3978/j.issn.2305-5839.2014.09.14

DO - 10.3978/j.issn.2305-5839.2014.09.14

M3 - Article

AN - SCOPUS:85015484827

SN - 2305-5839

VL - 2

JO - Annals of Translational Medicine

JF - Annals of Translational Medicine

IS - 9

M1 - 87

ER -

Galectins as therapeutic targets for hematological malignancies: A hopeful sweetness

Abstract

Bibliographical note

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this